<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026737</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC01419</org_study_id>
    <nct_id>NCT04026737</nct_id>
  </id_info>
  <brief_title>Cardiovascular Effects of CART Cell Therapy</brief_title>
  <acronym>CVE-CART</acronym>
  <official_title>Cardiovascular Effects of Chimeric Antigen Receptor T-Cell (CART Cell) Therapy: An Observational Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study aiming to prospectively define the rate of occurrence, natural
      history and progression of cardiac dysfunction in adults, and to identify the patients at
      high risk of developing cardiovascular events. The study enrolls patients prior to infusion
      with CART cell therapy and follows them with serial echocardiography, cardiac biomarkers,
      clinical data, and quality of life questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of Left Ventricular (LV) Dysfunction</measure>
    <time_frame>6 months</time_frame>
    <description>LV dysfunction, defined as a decrease in LV ejection fraction of at least 10% to less than or equal to 53%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cardiovascular Events</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiovascular events are defined as hospitalization for symptomatic congestive heart disease, nonfatal acute coronary syndrome, cardiovascular death, nonfatal stroke, and all-cause mortality</description>
  </secondary_outcome>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Cardiotoxicity</condition>
  <condition>Risk Factor, Cardiovascular</condition>
  <condition>Immunotherapy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients diagnosed with CD19+ malignancy (including but not limited to acute
        lymphoblastic leukemia, chronic lymphocytic leukemia, and difuse large B cell lymphoma) and
        scheduled for treatment with CART cells will be enrolled prior to infusion of CART cells.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Diagnosed with CD19+ malignancy undergoing treatment with CART cells

        Exclusion Criteria:

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Marielle Scherrer-Crosbie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marielle Scherrer-Crosbie, MD, PhD</last_name>
    <phone>215-662-4000</phone>
    <email>marielle.scherrer-crosbie@pennmedicine.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marielle Scherrer-Crosbie, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiotoxicity of Cancer Therapy</keyword>
  <keyword>Cardio-Oncology</keyword>
  <keyword>CART Cell Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

